2565 NW Lovejoy St. Suite 200 Portland, OR 97210
Phone: 503-226-3376
Fax: 503-223-9561

.

IMPORTANT- We are requiring all individuals that enter our clinic to wear a properly fitting face mask.

We are now accepting payments online through our patient portal.

flower_banner

Nails Psoriasis Publications

Click on the title to see the full article:

The Nail Psoriasis Severity Index (napsi) 13 years later: validation of an instrument to assess psoriatic nail involvement

The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3. randomized, placebo-controlled trial

The Nail Psoriasis Severity Index (NAPSI) 12 years later: Validation of an instrument to assess psoriatic nail involvement and a review of its use and controversy

Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3

Adalimumab for Nail Psoriasis: Efficacy and Safety from the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

How To Choose My Treatment

Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis

Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis results from the randomized and controlled as well as open-label phases of UNCOVER-3

The modified Nail Psoriasis Severity Index validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

Oregon Dermatology & Research Center - 2565 NW Lovejoy St., Portland, OR, 97210 - (503) 226-3376.